Teva and Eli Lilly end patent clash over migraine drug

Rival drugmakers have dropped lawsuit following invalidation of Teva patents in September | Move comes after judge overturned jury verdict handing $176.5m to Teva.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

Big Pharma

EU court confirms €60m fine for Teva

19 October 2023 Luxemboug court agrees with European Commission that ‘beneficial arrangement’ between Teva and Cephalon delayed generic market entry of sleep disorder drug | Teva and subsidiary Cephalon to pay around €30m each plus costs.

Americas

Corcept to ‘vigorously appeal’ Teva victory over Cushing’s syndrome drug patents

4 January 2024 California-based drugmaker lost Hatch-Waxman Act case after judge ruled it had failed to show patent infringement | Corcept CEO ‘confident’ decision will be reversed on appeal.

More on this story

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

Americas

Corcept to ‘vigorously appeal’ Teva victory over Cushing’s syndrome drug patents

4 January 2024 California-based drugmaker lost Hatch-Waxman Act case after judge ruled it had failed to show patent infringement | Corcept CEO ‘confident’ decision will be reversed on appeal.

Big Pharma

EU court confirms €60m fine for Teva

More on this story

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

Americas

Corcept to ‘vigorously appeal’ Teva victory over Cushing’s syndrome drug patents

4 January 2024 California-based drugmaker lost Hatch-Waxman Act case after judge ruled it had failed to show patent infringement | Corcept CEO ‘confident’ decision will be reversed on appeal.

Big Pharma

EU court confirms €60m fine for Teva